Sandra Calvin, SVP, CHIEF ACCOUNTING OFFICER at Travere Therapeutics, Inc. (TVTX), sold 34,244 shares at $25.00 ($856K) on 2025-02-11, disclosed to the SEC on 2025-02-12.
Scheduled sale ($856k) by SVP, CHIEF ACCOUNTING OFFICER under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $25.00 | 9,244 | $231K | 27.0% |
| 2 | $25.00 | 10,000 | $250K | 29.2% |
| 3 | $25.00 | 15,000 | $375K | 43.8% |
| Total | $25.00 avg | 34,244 | $856K | 100% |
| Filing → |
| TVTX | SELL | 2026-02-03 | $139K | — | Filing → |
| TVTX | SELL | 2025-12-29 | $296K | — | Filing → |
| TVTX | SELL | 2025-12-16 | $105K | — | Filing → |